Survodutide 10mg
Survodutide
CAS: 2253397-94-9
$143.99$159.9910% OFFIn Stock
Survodutide (BI 456906) is a dual GLP-1R/GcgR co-agonist in Phase 2/3 for obesity and NASH. NASH Phase 2 (SYNCHRONIZE) showed >40% of participants achieved NASH resolution. Emerging metabolic research compound. 98.5% HPLC purity.
Specifications
Vial Size10mg
FormLyophilized Powder
Purity98.5% HPLC
CAS2253397-94-9
Storage-20C long-term
For laboratory research use only. Not for human consumption.
Mechanism of Action
Simultaneous GLP-1R agonism for appetite/glucose control and GcgR agonism for hepatic fat oxidation and energy expenditure — a dual axis with particular relevance to NASH/MASH research.
Research FAQ
What distinguishes Survodutide from other GLP agonists?
Survodutide is a potent GcgR co-agonist with particularly strong NASH data — SYNCHRONIZE Phase 2 showed >40% NASH resolution rate, making it a focus for liver research alongside its weight loss profile.
